Home › Core › ISCC-IDs › 28CrZ57NK1Kbh

View ISCC-ID

Core Data

28CrZ57NK1Kbh
ISCC-ID - digital asset identifier
CCcThXadWpwfP-CTLJvQHQkUxef-CDTPAd3LkRe2j-CR2615NmU8aTA
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

867 therapy of childhood acute lymphoblastic leukemia all using adriamycin adr with or without high dose asparaginase asp

Ledger Reference

coblo
Source Ledger/Blockchain
12309393
N-th ISCC Decleration on source ledger
508a861cdb9cb203685a58cf31c99505d3a494fbaa7d00d09b0f8bf4d04b2f32
Hash of block that includes the ISCC-DECLARATION
fd7a7425a8bc08b82cf71b9f027763d8d7168b7459538b582317a8582cfdb9f7
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "867 THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) USING ADRIAMYCIN (ADR) WITH OR WITHOUT HIGH DOSE ASPARAGINASE (ASP)", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Stephen E Sallan", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://www.nature.com/articles/pr19811204.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Springer Science and Business Media LLC", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1203/00006450-198104001-00892", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCcThXadWpwfP-CTLJvQHQkUxef-CDTPAd3LkRe2j-CR2615NmU8aTA", "propertyID": "ISCC"}], "datePublished": "1981-04-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close